Puma Biotechnology, Inc.
10880 Wilshire Boulevard
Suite 2150
Los Angeles,
CA 90024
United States - Map
Phone: 424-248-6500
Fax: 424-248-6501
Website: http://www.pumabiotechnology.com
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California. Key Statistics
| |
| | Pay | Exercised | Mr. Alan H. Auerbach ,
43
Founder, Chairman, Chief Exec. Officer and Pres | 26.52M | 0.00 | Dr. Richard B. Phillips Ph.D.,
59
Sr. VP of Regulatory Affairs, Quality Assurance and Pharmacovigilance | 354.00K | 0.00 | Dr. Richard P. Bryce MBChB, MRCGP, MFPM,
55
Sr. VP of Clinical R&D | 235.00K | 0.00 | Mr. Charles R. Eyler ,
65
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. & Admin. and Treasurer | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.32(0.85%) 9:31AM EDT - Nasdaq Real Time Price